Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERG
Molecular Biology Reports · 2026
DOI: 10.1007/s11033-025-11258-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2026. Verfasst von Laura Segalés und 10 weiteren Autor:innen. Beteiligte Einrichtung: Departament of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Proto-Oncogene Protein c-ets-2, Tumor Suppressor Protein p53, Transcriptional Regulator ERG. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Spanish Ministry of Health, “Beca Leonardo de la Peña 2022” through the Foundation for Research in Urology of the Spanish Association of Urology.
Abstract (Originalsprache)
BACKGROUND: ETS2 expression in prostate cancer (PCa) shows variability, with overexpression and loss reported. ETS2 can be dysregulated through proteasomal degradation, but p53 missense mutants may stabilize ETS2 by preventing this process. TP53 mutations are more frequent in metastatic PCa, and their identification in primary tumors could serve as an early marker for patient stratification. In addition, TMPRSS2-ERG fusion often arises from an intrachromosomal deletion including ETS2 locus. METHODS AND RESULTS: ETS2, p53 and ERG protein expression were assessed by immunohistochemistry in a surgically treated PCa patients' cohort (N = 199). ETS2 and TMPRRS2-ERG mRNA were evaluated by qPCR in an independent series (N = 80). Relationship between molecular markers, and with clinicopathological characteristics was analyzed. High ETS2 protein expression was observed in 34.7% of tumors. Aberrant p53 immunostaining was detected in 5.5% of cases, being associated with high ETS2 expression (p = 0.050). p53 positivity was related to GG5 (p = 0.007) and unifocality (p = 0.011). Shorter time to PSA recurrence was observed in p53-positive patients (p = 0.002). Cases with high ETS2 expression but negative p53 staining had the longest time to recurrence, whereas p53-positive cases, regardless of ETS2, had the shortest (p = 0.002). ERG protein expression -surrogate marker of TMPRSS2-ERG- was strongly associated with high ETS2 (p < 0.001). At mRNA level, low ETS2 expression correlated with TMPRSS2-ERG fusion (p = 0.018), and showed a trend toward association with intrachromosomal deletion (p = 0.113) and high-stage (p = 0.054). CONCLUSIONS: In conclusion, p53 staining was consistently associated with aggressive PCa and may serve as a reliable prognostic marker. High ETS2 expression correlates with delayed PSA recurrence in p53-negative tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departament of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
- Hospital del Mar Research Institute, Barcelona, Spain.
- Department of Pathology, Hospital del Mar, Barcelona, Spain.
- Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
- Department of Urology, Hospital del Mar, Barcelona, Spain.
- Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Förderung
- Spanish Ministry of Health
- “Beca Leonardo de la Peña 2022” through the Foundation for Research in Urology of the Spanish Association of Urology
Zitieren
APA
Segalés, L., Juanpere, N., Lorenzo, M., Casado, B., de Muga, S., Salido, M., Rodriguez-Vida, A., Fumadó, L., Cechinni, L., Bellmunt, J., & Hernández-Llodrà, S. (2026). Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERG. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-11258-9
Vancouver
Segalés L, Juanpere N, Lorenzo M, Casado B, de Muga S, Salido M, et al. Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERG. Molecular Biology Reports. 2026. doi:10.1007/s11033-025-11258-9
BibTeX
@article{Segals2026,
author = {Segalés, Laura and Juanpere, Nuria and Lorenzo, Marta and Casado, Beatriz and de Muga, Sílvia and Salido, Marta and Rodriguez-Vida, Alejo and Fumadó, Lluís and Cechinni, Lluís and Bellmunt, Joaquim and Hernández-Llodrà, Silvia},
title = {Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERG},
journal = {Molecular Biology Reports},
year = {2026},
doi = {10.1007/s11033-025-11258-9}
}
EUVIMED